Technology investment specialist Mercia Fund Management is launching a new fund offering tax-efficient investment in the UK’s fast-growing digital economy. The Mercia Digital Fund will utilise the hybrid structure of Mercia’s previous three tax efficient funds, combining the Enterprise Investment Scheme (EIS) and Seed Enterprise Investment Scheme (SEIS), to invest in a diversified portfolio of
Henley-in-Arden, 30 July 2014 – Technology investor Mercia Fund Management has announced that portfolio company,Oxford Genetics Ltd, has now secured £330,000 in funding in total, including a £100,000 TSB Smart Award. Oxford Genetics is the biotechnology company behind SnapFast™ – a system that simplifies the purchase of synthetic DNA molecules (plasmids). Since its first round
Drug screening services spinout secures investment package Henley-in-Arden, 21 July 2014. Technology investor Mercia Fund Management has announced a £229,000 investment in InoCardia, a Coventry University spinout providing drug screening services. Mercia Fund Management’s investment will fund the development and commercialisation of a pre-clinical drug testing service for pharmaceutical organisations. Dr Helen Maddock – an
Henley-in-Arden, UK, 18 July 2014. Technology specialist Mercia Fund Management forecasts an increased demand for capital growth focused tax efficient investments in the wake of the Finance Bill that received Royal Assent yesterday. The Bill closes a loophole enabling Enterprise Investment Schemes (EIS) and Seed EISs (SEIS) to invest in renewable energy projects that enjoy
Specialist technology investor Mercia Fund Management (Mercia) says today’s successful flotation on AIM of life sciences company Abzena plc represents a substantial uplift for its investors and a belief in substantial further growth to come. Mercia was part of the syndication that provided the recent £13.5 million in funding to the biopharmaceuticals testing company in
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, THE REPUBLIC OF IRELAND OR THE COMMONWEALTH OF AUSTRALIA 7 July 2014 London, UK – Abzena plc (“Abzena”, the “Group” or the “Company”), a revenue-generating life sciences company providing services and technologies that enable
Mercia Fund Management is pleased to announce that Abzena Limited (‘Abzena’), formerly known as PolyTherics, has today announced its intention to proceed with an initial public offering and to seek Admission of its shares to AIM. Abzena is focused on providing proprietary technologies and value-added services to enable the development of better biopharmaceuticals. The company
Free-to-play game developer secures SEIS investment package Henley-in-Arden, 9 June 2014. Venture capital fund manager Mercia Fund Management (MFM) has announced a Seed Enterprise Investment (SEIS) in game developer and publisher Dab Gaming. Dab Gaming builds and operates mobile free-to-play games and has recently launched its debut game BingoDab, bringing the excitement of playing real
London, UK and Dallas, TX, USA, 6 June 2014 – Antitope Limited (“Antitope”), an Abzena company, today announced that it will develop a manufacturing cell line for the Baylor Institute for Immunology Research (“BIIR”), one of the world’s leading centres for translational immunology research, using its Composite CHOTM technology. BIIR is developing a range of
Leading UK technology investor looks to attract innovative technology companies Henley-in-Arden, 3 June 2014. Mercia Fund Management (MFM), a leading technology investor, in partnership with the newly launched Forward House Workspace, is inviting early stage UK technology businesses to pitch their business plans and compete in ‘The Mercia Investment Pitch 2014’. Businesses must have been